Classes
Publications
- Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death +12009 | Faculty of Medicine in Hradec Králové
- Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH) +12007 | Faculty of Medicine in Hradec Králové
- New iron chelators in anthracycline-induced cardiotoxicity +12007 | Faculty of Medicine in Hradec Králové
- Evaluation of in vitro protection by salicylaldehyde isonicotinoyl hydrazone (SIH) against hydrogen peroxide-and anthracycline-induced toxicity to cardiac cellsPublication without faculty affiliation
- Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up2022 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Development of a Rat Model of Intra-Amniotic Inflammation via Ultrasound-Guided Administration of a Triggering Agent in the Gestational Sac to Enable Analysis of Individual Amniotic Fluid Samples2022 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
Loading network view...